The trial will explore the effects of higher doses of ACD856, building on the drug’s established safety profile.

In diseases like Parkinson's and Alzheimer's, specific proteins misfold and clump together, forming toxic aggregates that ...

The factor that tips you over the edge from being at risk for a disease to actually developing the disease is not always ...

Researchers have developed a novel analytical method for tracking disease progression in patients that shows great potential ...

A new discovery from an international collaborative research team has solved the mystery of how cells turn on their recycling ...

Losing NIH funding, according to Dr. Lipton, would stop the research done at Michigan State University's College of Human ...

An expert has shed light on the upsides of a superfood that he claims is simple to add into your diet. Lion's mane mushrooms, ...

An expert has highlighted the benefits of lion's mane mushrooms, a superfood that's easy to incorporate into your diet and is ...

TELO READ THE FULL TELO RESEARCH REPORT Telomir Pharmaceuticals (NASDAQ:TELO) is a preclinical stage biopharmaceutical company developing a product designed to lengthen the DNA’s protective telomere ...

Cleveland Clinic researchers are using artificial intelligence to identify existing FDA-approved drugs that may be repurposed to treat other complex diseases. The effort is led by Feixiong Cheng, PhD, ...

AbbVie's growth thrives on strong earnings, a robust immunology portfolio, and diversification. See why ABBV stock is a ...

BioArctic AB's (publ) partner Eisai has notified BioArctic that the first sales milestone according to the licensing agreement has been reached. The milestone was reached as sales of Leqembi reached ?